Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Tonix Pharma ( (TNXP) ).
On August 15, 2025, Tonix Pharmaceuticals announced FDA approval for Tonmya, a treatment for fibromyalgia in adults, with availability expected in the U.S. by the fourth quarter of 2025. The approval was based on successful Phase 3 trials showing significant pain reduction and good tolerability, positioning Tonix as a key player in the fibromyalgia treatment market.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s strong technical indicators and positive corporate events are offset by financial challenges and valuation concerns. The company’s growth potential is evident, but profitability and reliance on external funding remain significant risks.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on developing therapies for central nervous system disorders. The company’s primary product, Tonmya, is designed for the treatment of fibromyalgia in adults.
Average Trading Volume: 1,292,466
Technical Sentiment Signal: Sell
Current Market Cap: $522.3M
For an in-depth examination of TNXP stock, go to TipRanks’ Overview page.